Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ
Closed
Oct 20, 2026
Day's Range
4.0552 wk Range
3.10Overview - BOLT - Bolt Biotherapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
11.94M
P/E (Trailing)
‪-0.24‬
P/E (Forward)
‪-0.20‬
PEG Ratio
‪-0.09‬
Price / Sales (TTM)
‪1.68‬
Price / Book
‪0.62‬
EV / EBITDA
‪-0.43‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-151,320.00%‬
Return on Assets
‪-30.72%‬
Return on Equity
‪-111.64%‬
Ownership
Shares Outstanding
1.92M
Float
1.62M
Short % of Shares Outstanding
‪1.34%‬
Held by Insiders
‪3.46%‬
Held by Institutions
‪27.92%‬
Price stats
Beta
‪1.00‬
50-Day Avg
‪3.70‬
200-Day Avg
‪4.55‬
Analyst Consensus
4 analysts
Average price target
‪$ 29.00‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BOLT - Bolt Biotherapeutics, Inc.
Peers - BOLT - Bolt Biotherapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BOLTNASDAQBolt Biotherapeutics Inc.8.16MMarket Cap-36.79%52-week change-0.24P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - BOLT - Bolt Biotherapeutics, Inc.
About
Bolt Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. The company harnesses the immune system through its proprietary Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, which combines tumor-targeting antibodies with…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
